BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 14, 2025
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

June 11, 2020

View Archived Issues
Minimed 780G product image

Medtronic scores CE mark for Minimed 780G insulin pump

Medtronic plc, of Dublin, has gained CE-marking approval for its Minimed 780g system, a next-generation closed-loop insulin pump for people with type 1 diabetes between the ages of 7 and 80 years old. The advanced hybrid closed-loop system (AHCL) features an advanced autocorrection algorithm and Bluetooth connectivity. Read More
patent-law.png

Merck unable to make written description argument in patent dispute with Microspherix

The patent lawsuit between Merck & Co. and Microspherix LLC began when the latter sued Merck for infringement of patents for brachytherapy in Merck’s implantable contraceptive device, but Merck was unable to prevail in an inter partes review (IRP) or in an appeal of the IPR at the Court of Appeals for the Federal Circuit. After wading through questions about purported prior art, Merck failed to persuade the two courts that Microspherix’s non-provisional filing had strayed too far from the written description of the related provisional, thus handing Microspherix a win against its much larger rival in the market for drug delivery with microspheres. Read More
Clinical trial patient tested

Illumina EUA brightens future of COVID-19 diagnostic tests and analysis

The U.S. FDA granted San Diego-based Illumina Inc. an emergency use authorization (EUA) for the first COVID-19 diagnostic test that uses next-generation sequencing (NGS). In addition to diagnosing infection with SARS-CoV-2, the COVIDSeq test can help researchers track mutations in the coronavirus. Read More
coronavirus-antibodies-immunity.png

Adaptive, Microsoft launch open database of immune response by COVID-19 patients

Partners Adaptive Biotechnologies Corp., which is based in Seattle, and Redmond, Wash.-based Microsoft Corp. have started sharing an open database that details the immune response in COVID-19 patients with researchers and public health officials. The project is analyzing thousands of de-identified patient blood samples submitted from institutions around the world and is dubbed ImmuneCODE. Read More
Asia-India-country-flag-map.png

India starts easing restrictions on med-tech exports, promises domestic priority

HONG KONG – India has been slowly easing restrictions on the export of its med-tech products, giving hope to domestic manufacturers looking to meet global demand for their output. “We are pleased to share that many of the routine IVD diagnostic kits falling under HSN code 3822 have been removed from export restrictions and a few specific items related to COVID-19 testing retained,” Rajiv Nath, the forum coordinator for the Association of Indian Medical Device Industry (AIMED), told BioWorld recently. Read More

Appointments and advancements for June 11, 2020

New hires and promotions in the med-tech industry, including: Conversa Health, Quidel, Titan Medical. Read More

Financings for June 11, 2020

Med-tech firms raising money in public or private financings, including: Biolase, Catalent, Conversa Health, Livanova, Titan Medical. Read More

In the clinic for June 11, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Random Walk Imaging, Veracyte. Read More

Other news to note for June 11, 2020

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Berry Genomics, Biospherix, Dariohealth, Genetron, Hawkeye Systems, Htg Molecular Diagnostics, Nanotronics, Patientsafe Solutions, Personalis, Royal Philips, Sexton Biotechnologies, Sorrento Therapeutics, Terramera, Thermo Fisher Scientific. Read More

Regulatory actions for June 11, 2020

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Establishment Labs, Medtronic. Read More

Regulatory front for June 11, 2020

The latest global regulatory news, changes and updates affecting medical devices and technologies, including: Lucid Diagnostics, Moleculight, Palmetto GBA, Pavmed. Read More

BioWorld MedTech’s Diagnostics Extra for June 11, 2020

Keeping you up to date on recent developments in diagnostics, including: Sickle cell still greatly undiagnosed; Cardiac imaging for heart strain in infants with lung infections; C12orf49 is new lipid metabolism gene. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 12, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 12, 2025.
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • Illustration of head with maze that is missing parts

    CTAD 2025: The challenges of combination therapies for dementia

    BioWorld Science
    At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
  • Brain and encephalography

    DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

    BioWorld
    Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing